Today: 30 April 2026
Browse Category

NYSE:ULTY 7 December 2025

YieldMax Ultra Option Income Strategy ETF (ULTY) Stock: 2025 Price, 77% Yield, Reverse Split and 2026 Outlook

YieldMax Ultra Option Income Strategy ETF (ULTY) Stock: 2025 Price, 77% Yield, Reverse Split and 2026 Outlook

YieldMax Ultra Option Income Strategy ETF (ULTY) closed at $39.98 on December 5, 2025, following a 1-for-10 reverse split and a year-to-date price drop of about 60%. The fund’s official distribution rate stands at 76.99%, with some data showing a trailing 12-month yield above 120%. Assets under management are near $1.4 billion. ULTY charges a 1.30% expense ratio and holds about 80–100 positions.
7 December 2025
··

Stock Market Today

  • Cartier Heir Sentenced to 8 Years for $470M Drug Money Crypto Laundering Scheme
    April 30, 2026, 3:26 PM EDT. Maximilien de Hoop Cartier, descended from the Cartier jewelry family, was sentenced to eight years in federal prison for running an unlicensed cryptocurrency exchange that laundered over $470 million in drug money. The scheme involved shell companies posing as software firms and broke transactions into smaller amounts to evade bank detection. Cartier pleaded guilty to money transmission without a license and bank fraud conspiracy in Manhattan federal court. Authorities seized nearly $940,000 in 2021, and Cartier was ordered to forfeit over $2.3 million and multiple bank accounts. U.S. Attorney Jay Clayton condemned Cartier's exploitation of financial systems for laundering drug proceeds. Cartier also maintains a social media presence as a singer under the name 'Max Cartier.'

Latest article

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

30 April 2026
Rezolve AI reported $60 million in first-quarter revenue, surpassing its audited 2025 total of $46.8 million, based on unaudited accounts. Shares rose 4.9% after the update. The company reaffirmed its $360 million 2026 revenue target and said it can reach profitability without new equity sales. Commerce.com, which rejected Rezolve’s all-stock takeover offer, adopted a poison pill defense.
Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

30 April 2026
Option Care Health shares fell 28% to $19.44 after the company cut its 2026 revenue forecast and reported first-quarter sales of $1.35 billion, missing estimates. The company now expects 2026 revenue of $5.675–$5.775 billion, down from a prior range of $5.8–$6.0 billion, citing pressure in its chronic inflammatory disease portfolio. Adjusted profit guidance was unchanged.
Stellantis N.V. Stock Slides: Q1 Profit Rebound Leaves One Big Cash-Flow Question

Stellantis N.V. Stock Slides: Q1 Profit Rebound Leaves One Big Cash-Flow Question

30 April 2026
Stellantis reported a first-quarter net profit of €377 million, reversing a €387 million loss a year earlier, aided by a €400 million expected U.S. tariff refund. Industrial free cash flow remained negative at €1.92 billion. Shares fell 6.4% to €6.22 after the results. CEO Antonio Filosa faces pressure ahead of a May 21 investor day to present a stronger turnaround plan.
Go toTop